Kristel Paque1, Monique Elseviers2, Robert Vander Stichele3, Tinne Dilles4, Koen Pardon5, Luc Deliens6, Thierry Christiaens7. 1. Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, C. Heymanslaan 10, 9000 Gent, Belgium; End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Laarbeeklaan 103, 1090 Brussels, Belgium. Electronic address: kristel.paque@ugent.be. 2. Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, C. Heymanslaan 10, 9000 Gent, Belgium; Faculty of Medicine and Health Sciences, Department of Nursing Science, Centre for Research and Innovation in Care (NuPhaC), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Electronic address: monique.elseviers@uantwerpen.be. 3. Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, C. Heymanslaan 10, 9000 Gent, Belgium. Electronic address: robert.vanderstichele@ugent.be. 4. Faculty of Medicine and Health Sciences, Department of Nursing Science, Centre for Research and Innovation in Care (NuPhaC), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium; Department of Nursing and Midwifery, Thomas More University College, Antwerpsestraat 99, 2500 Lier, Belgium. Electronic address: tinne.dilles@uantwerpen.be. 5. End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Laarbeeklaan 103, 1090 Brussels, Belgium. Electronic address: koen.pardon@vub.be. 6. End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Laarbeeklaan 103, 1090 Brussels, Belgium; Department of Public Health and Primary Care, Ghent University Hospital, C. Heymanslaan 10, 9000 Gent, Belgium. Electronic address: luc.deliens@vub.be. 7. Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, C. Heymanslaan 10, 9000 Gent, Belgium. Electronic address: thierry.christiaens@ugent.be.
Abstract
BACKGROUND: Survival in older adults has a high variability. The possible association of length of survival with potentially inappropriate medication (PIM) use remains unclear. AIM: To examine the four-year survival rate, the prevalence of polypharmacy and PIM use at admission, and the association between the two, in an inception cohort of newly admitted nursing home residents METHODS: Data were used from ageing@NH, a prospective observational cohort study in nursing homes. Residents (n = 613) were followed for four years after admission or until death. PIM use was measured at admission, using STOPPFrail. The Kaplan-Meier method was used to estimate survival, using log-rank tests for subgroup analyses. Cox regression analyses was used to explore associations with PIM use and polypharmacy, corrected for covariates RESULTS: Mean age was 84, 65% were females. After one, two, three and four years the survival rates were respectively 79%, 60.5%, 47% and 36%. At admission, 47% had polypharmacy and 40% excessive polypharmacy, 11% did not use any PIMs, and respectively 28%, 29%, and 32% used one, two and three or more PIMs. No difference in survival was found between polypharmacy and no polypharmacy, and PIM use and no PIM use at admission. Neither polypharmacy nor PIM use at admission were associated with mortality. CONCLUSION: Residents survived a relatively short time after NH admission. Polypharmacy and PIM use at admission were relatively high in this cohort, although neither was associated with mortality.
BACKGROUND: Survival in older adults has a high variability. The possible association of length of survival with potentially inappropriate medication (PIM) use remains unclear. AIM: To examine the four-year survival rate, the prevalence of polypharmacy and PIM use at admission, and the association between the two, in an inception cohort of newly admitted nursing home residents METHODS: Data were used from ageing@NH, a prospective observational cohort study in nursing homes. Residents (n = 613) were followed for four years after admission or until death. PIM use was measured at admission, using STOPPFrail. The Kaplan-Meier method was used to estimate survival, using log-rank tests for subgroup analyses. Cox regression analyses was used to explore associations with PIM use and polypharmacy, corrected for covariates RESULTS: Mean age was 84, 65% were females. After one, two, three and four years the survival rates were respectively 79%, 60.5%, 47% and 36%. At admission, 47% had polypharmacy and 40% excessive polypharmacy, 11% did not use any PIMs, and respectively 28%, 29%, and 32% used one, two and three or more PIMs. No difference in survival was found between polypharmacy and no polypharmacy, and PIM use and no PIM use at admission. Neither polypharmacy nor PIM use at admission were associated with mortality. CONCLUSION: Residents survived a relatively short time after NH admission. Polypharmacy and PIM use at admission were relatively high in this cohort, although neither was associated with mortality.
Authors: Stéphane Sanchez; Jan Chrusciel; Biné Mariam Ndiongue; Caroline Blochet; Jean François Forget; Aude Letty; Paul Emile Hay; Jean Luc Novella Journal: Int J Environ Res Public Health Date: 2021-12-31 Impact factor: 3.390
Authors: Jennifer Tjia; Jennifer L Lund; Deborah S Mack; Attah Mbrah; Yiyang Yuan; Qiaoxi Chen; Seun Osundolire; Cara L McDermott Journal: Curr Epidemiol Rep Date: 2021-04-23
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; João Paulo Neves Mota; Ana Elisa Bauer de Camargo Silva; Rafael Alves Guimarães; Valéria Pagotto Journal: PLoS One Date: 2020-10-28 Impact factor: 3.240